434 results about "Adverse effect" patented technology

A composition of a compound represented by FIGS. 1A-1E for use in treating a medical disorder. A method of changing neurotransmission, by administering a pharmaceutically effective amount of composition to a mammal of a compound represented by FIGS. 1A-1E and inducing psychoactive effects in the mammal. A method of treating a patient having adverse reactions to psychedelics or entactogens, by administering a pharmaceutically effective amount of composition to the patient of a compound represented by FIGS. 1A-1E and avoiding adverse effects present with psychedelics or entactogens.

The invention relates to novel compositions and methods of using maribavir which enhance its effectiveness in medical therapy, as well as to maribavir isomers and methods of use thereof for counteracting the potentially adverse effects of maribavir isomerization in vivo in the event it occurs.

Embodiments disclosed herein include methods and systems for managing outcomes for weight-loss GLP-1 receptor agonist therapies using biochemical data-trained models and / or other patient centric analysis. In some embodiments, one or more biomarkers or other patient data are employed for training AI / ML or other computational models and / or as inputs to AI / ML or other computational models to evaluate patient response to GLP-1 receptor agonist therapy. For example, the computational models may be configured to perform classifications with respect to success of GLP-1 receptor agonist therapy and / or adverse effects during GLP-1 receptor agonist therapy.

The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.

A pharmaceutical composition comprises a GPCR agonist fusion protein in which a GPCR agonist peptide is covalently coupled to albumin via a linker in a manner that is resistant to a retro-Michael addition. Advantageously, compositions presented herein avoid decoupling of the agonist form the albumin while retaining the agonist in a steric relationship to the albumin that allows for effective binding and activation of the GPCR while also enabling gp60-mediated transcytosis and FcRn-mediated albumin recycling. These properties enable ultra-low dosages for the GPCR agonist fusion protein to give a therapeutic effect while substantially reducing or even entirely avoiding adverse effects otherwise commonly associated with unbound agonists. Such retro-Michael resistant composition is generally achieved by conformational modification of the albumin, resulting in stereoselective coupling of the linker to the albumin.

The invention relates to a traditional Chinese medicine composition for treating allergic dermatitis. The traditional Chinese medicine composition is prepared from the following traditional Chinese medicines in parts by weight: 5-35 parts of fried coix seeds, 5-35 parts of concha margaritifera, 1-30 parts of honeysuckle stems, 1-30 parts of smoked plums, 1-30 parts of fructus liquidambaris, 1-25 parts of fructus forsythiae, 1-25 parts of radix paeoniae rubra, 1-25 parts of raw sanguisorba officinalis, 1-25 parts of radix glehniae, 1-25 parts of radix ophiopogonis and 1-25 parts of raw radix polygonati officinalis. 1-25 parts by weight of talc and 1-25 parts by weight of lophatherum gracile. The traditional Chinese medicine composition has the effects of clearing heat, cooling blood without bitter cold, dispelling wind, eliminating dampness without hurting stomach, detoxifying, relieving itching and nourishing yin, is safe in clinical use, and has no adverse effect on liver and kidney.

To provide methods of treating a B-cell proliferative disorder.SOLUTION: The present invention relates to methods of treating a B-cell proliferative disorder by administering an anti-CD20 / anti-CD3 bispecific antibody, and methods for reduction of adverse effects in response to the administration of the anti-CD20 / anti-CD3 bispecific antibody. The present invention further relates to combination treatment methods of treating a B-cell proliferative disorder.SELECTED DRAWING: None

The present invention provides for the immediate or chronic administration of certain potassium ATP (K ATP ) channel openers, optionally in combination with growth hormone, to subjects to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic, and compositional outcomes in the treatment of diseases or conditions involving K ATP channels. Also provided are pharmaceutical formulations, methods of administration, and methods of dosing K ATP channel openers to achieve these outcomes and to reduce the incidence of adverse effects in treated individuals. Also provided are methods of co-administering K ATP channel openers with other drugs, e.g., in combination with growth hormone, to treat diseases in humans and animals, e.g., Prader-Willi Syndrome (PWS), Smith-Magenis Syndrome (SMS), etc.

A pharmaceutical composition comprises a GPCR agonist fusion protein in which a GPCR agonist peptide is covalently coupled to albumin via a linker in a manner that is resistant to a retro-Michael addition. Advantageously, compositions presented herein avoid decoupling of the agonist form the albumin while retaining the agonist in a steric relationship to the albumin that allows for effective binding and activation of the GPCR while also enabling gp60-mediated transcytosis and FcRn-mediated albumin recycling. These properties enable ultra-low dosages for the GPCR agonist fusion protein to give a therapeutic effect while substantially reducing or even entirely avoiding adverse effects otherwise commonly associated with unbound agonists. Moreover, these properties also enable transport of the GPCR agonist fusion protein across the blood brain barrier and therefore allow treatment of neural disorders.

The invention belongs to the technical field of biological medicines, and particularly relates to a preparation method and application of a plant extract. The tartary buckwheat active polypeptide is prepared by performing enzymolysis reaction on tartary buckwheat protein. The tartary buckwheat active polypeptide can effectively inhibit the activity of angiotensin converting enzyme (ACE), so that the tartary buckwheat active polypeptide can be used as an ACE inhibitor to reduce blood pressure. The plant extract disclosed by the invention not only has the functions of high-efficiency antihypertensive effect, no toxicity, no side effect and the like, but also has the advantages of simplicity in preparation, easiness in absorption and the like, and avoids adverse effects of side effects of traditional chemical medicines on human bodies.

The invention discloses a tumor radiotherapy non-irradiation area protection device, and relates to the cervical cancer radiotherapy protection field, and the tumor radiotherapy non-irradiation area protection device comprises a mounting frame, and the interior of the mounting frame is fixedly connected with a first telescopic driving member. The first moving mechanism and the second moving mechanism can respectively drive the moving frame and the adjusting plate to move back and forth and left and right, so that the through hole is accurately positioned to the radiotherapy position of the cervical cancer patient. The first rotation driving piece can drive the adjusting lead plate to rotate, so that the adjusting holes with proper sizes are aligned with cancer cells. The blocking adjusting mechanism further optimizes protection, and when a gap exists between the adjusting hole and the cancer cells, the driving mechanism drives the transmission ring to rotate, so that the second telescopic driving piece drives the pushing block to push the lead block plate to move, and the gap is filled. Thus, the first lead plate, the second lead plate and the adjusting lead plate act together to ensure that radiotherapy rays irradiate cancer cells only through the adjusting holes, so that the rays are effectively prevented from damaging surrounding healthy tissues, and adverse effects of radiotherapy on patients are reduced.

The invention is suitable for the technical field of urinary surgery, and particularly relates to a bladder pressure control method and system and transurethral surgery operation equipment. Wherein the bladder environment information comprises a bladder environment model and blood vessel distribution information; the bladder pressure is monitored in real time; wherein the bladder pressure reflects the pressure in the bladder in the operation process; obtaining a perfusion speed and a discharge speed based on the bladder pressure; when a pre-operation instruction is received, the perfusion adjustment speed and the discharge adjustment speed are obtained based on the pre-operation instruction and the bladder environment information; wherein the pre-operation instruction is an instruction which is sent by a doctor and is used for controlling a cutting instrument to cut a tumor or a basal wound surface. According to the bladder pressure control method and system and the transurethral surgery operation equipment provided by the embodiment of the invention, the problem that pressure rise in the bladder causes adverse effects on the safety of a patient and postoperative recovery can be solved.

An antibody against CEACAM5 and CEACAM6 or antigen-binding fragment thereof, and the use thereof. The antibody is an antibody against CEACAM5 and CEACAM6, which antibody has a good performance, and can specifically bind to both targets CEACAM5 and CEACAM6 with a high affinity, thereby expanding antibody indications. The antibody against CEACAM5 and CEACAM6 has a binding specificity, hardly binds to normal cells, and only binds to overexpressed tumor cells, thereby reducing adverse effects caused by non-specific binding. The antibody also has a good endocytosis activity, and can be used for coupling a cytotoxic drug to form an antibody-drug conjugate for anti-tumor therapy.

The invention belongs to the technical field of biological medicine, and particularly relates to a preparation method and application of plant polypeptide. The schisandra chinensis active polypeptide is prepared by carrying out enzymolysis reaction on schisandra chinensis protein. The schisandra chinensis active polypeptide can effectively inhibit the activity of angiotensin converting enzyme (ACE), so that the schisandra chinensis active polypeptide can be used as an ACE inhibitor to reduce blood pressure. The plant extract disclosed by the invention not only has the functions of high-efficiency antihypertensive effect, no toxicity, no side effect and the like, but also has the advantages of simplicity in preparation, easiness in absorption and the like, and avoids adverse effects of side effects of traditional chemical medicines on human bodies.

The present invention relates to a GFRAL-antagonistic antibody and a use thereof, and more particularly, to an anti-GFRAL antibody comprising a heavy chain CDR and a light chain CDR of specific sequences, and an antigen-binding fragment thereof. The anti-GFRAL antibody is expected to be usefully utilized for ameliorating or treating anorexia-cachexia syndrome associated with cancer, and adverse effects of chemotherapeutic drugs.

Provided is a bispecific antibody and use thereof, the bispecific antibody comprising: a first domain that specifically binds the interleukin-6 receptor IL-6R, and a second domain that specifically binds interleukin-23. The bispecific antibody can simultaneously target IL-6R and IL-23p19, with stronger specificity, more accurately targeting tumor cells and reducing the adverse effects of off-target toxicity and can perform a unique function to play a biological function that is difficult to achieve with monoclonal antibody drugs. Compared with monoclonal antibody combination therapies, it can also effectively reduce the cost of treatment and break the current upper limit of therapeutic efficacy in the treatment of autoimmune diseases such as rheumatoid arthritis and IBD.

Methods and products are provided for preventing or reducing adverse effects of glucose withdrawal, improving cognitive function, and promoting sustained ketosis. Disclosed is a beverage formulation with optimized ketone salts, antioxidants, and metabolic cofactors. Additionally, a computing system generates personalized supplement formulations based on individual health data to enhance efficacy and compliance.

The application provides a Guizhou Rhamnus skin wound healing ointment and a preparation method thereof, and relates to the technical field of traditional Chinese medicine compositions. The ointment comprises Guizhou Rhamnus concentrated extract and base excipients. The ointment has the functions of promoting skin wound healing, preventing swelling and pain, preventing infection and scar, reducing swelling and pain, removing blood stasis and promoting tissue regeneration, dredging channels and activating collaterals, and healthy skin tissue. The active ingredients of traditional Chinese medicine have the advantages of rapid healing and repair, obvious swelling and pain relief, delicate ointment texture, easy absorption by the skin, high safety, good stability, wide source of raw materials, easy collection, simple preparation process, batch processing, no toxic side effects on the health of production personnel, and no adverse effects on the environment.

The invention discloses a herbal medicine composition and application thereof. The herbal medicine composition comprises the following components in percentage by mass: 5%-85% of an extract of Indian ginseng, 5%-85% of an extract of rhodiola rosea, 5%-85% of an extract of melissa officinalis and 5%-85% of an extract of holy basil. The herbal composition is a natural composition that effectively supports mental health while minimizing adverse effects and promoting overall health; in particular, the herbal composition can achieve effects including "coordinated regulation of multiple neurotransmitter systems", "multi-target regulation of an HPA axis", "coordinated enhancement of an antioxidant system", "coordinated promotion of neuronutrition and neuroplasticity", "a synergistic effect of inflammation regulation", and "a synergistic effect of gene expression regulation".

The application discloses an arteriovenous fistula system, and relates to the technical field of medical devices, which comprises a fistula catheter, a handle, a power transmission line and a power output controller. The application makes the operation of the fistula catheter head more convenient, realizes accurate detection of the relative displacement amount of the head electrode, makes the fistula catheter head not loosen even if the external force disappears after being closed, improves the structure of the heating electrode, and makes the size and angle of the fistula not adversely affect the blood flow. The application adds blood flow, blood pressure, temperature and other sensors in the fistula catheter, cooperates with the control function of the power output controller, realizes accurate detection of the opening and closing state of the fistula catheter head, automatic detection of the arteriovenous vessel wall capture, safe output of energy and heating control of the fistula catheter head electrode. The application is more beneficial to the operation of doctors in clinical use and can obtain better fistula effect.

The invention discloses a composition for improving adverse effects of chemotherapy as well as a preparation method, application and a product of the composition, and particularly relates to the technical field of medicines. The composition comprises the following raw materials: tortoise, soft-shelled turtle, antler, sea cucumber, fructus amomi, pericarpium citri reticulatae and hawthorn. Alkaline protease and flavourzyme are adopted for enzymolysis, and the obtained composition can remarkably reduce the tumor volume of tumor-bearing animals, increase the bone marrow DNA content of chemotherapy animals and remarkably increase the number of white blood cells and the number of red blood cells in peripheral blood of the chemotherapy animals. The composition disclosed by the invention is used for preparing related products for improving the adverse effects of chemotherapy, and the prepared products are easy to absorb and have a remarkable improvement effect on the adverse effects of chemotherapy.

The present invention relates to the field of characterizing microbiota present on human skin. More specifically, the present invention relates to a device for revealing a skin-microbiota complex in an immunochromatographic manner, the device allows for rapid and meaningful biological determination of two members of skin-microbiota symbiosis by means of immunological characterization of biomarkers available on the surface of the microbiota-skin interacting group. Artificial intelligence is then used to recommend optimal care that is suitable for the skin type on the one hand and compatible with its microbiota on the other hand, thereby reducing the risk of adverse effects. Similarly, in the case of skin flaws and / or microbiota imbalances, the present invention will recommend optimal corrective treatments to ensure compatibility with or be able to modulate microbiota.

This invention discloses a method for preparing a composite spray that improves hemostasis at wound sites. The composite spray includes solution A and solution B, where solution B is an aqueous solution of sodium alginate. The preparation method of solution A includes: 1. Dissolving a lipopeptide conjugate, cholesterol, distearylphosphatidylcholine, distearylphosphatidylserine, and dimethyl sulfoxide in a chloroform-methanol mixed solution to obtain a mixed system; 2. Preparing a precursor solution from the mixed system using a thin-film hydration method; 3. Adding calcium chloride to the precursor solution and reacting it in the dark to obtain solution A. This invention designs the precursor solution based on the function of natural platelets, and its function is equivalent to that of nanoplatelets. Combined with sodium alginate, it can specifically alleviate the adverse effects on the coagulation system caused by blood loss, such as fibrin degradation and reduced platelet activation, at wound sites. It has the characteristics of rapid hemostasis, good bioactivity, and rapid wound healing.

A C-terminal fragment of insulin-like growth factor binding protein 2 (IGFBP2) containing 3 cysteine residues has been shown to spontaneously self-assemble into nanotube (NT) structures. These NTs can encapsulate drugs during the assembly process and then deliver their cargo intracellularly following binding to interns and endocytosis. The integrin-dependence of this process is mediated by the presence of a naturally occurring RGD motif within the peptide sequence. A particular advantage of such NTs is that by encapsulating small molecule drugs, tissues are protected from their adverse effects. Here, the use of NTs to deliver small drugs and biologics across the blood-brain barrier (BBB) by penetrating the CNS and delivering their cargo is described.

The utility model relates to the field of medical instruments, in particular to a fixing device for a central venous catheter, which comprises a fixing band and a fixing component, the fixing component is arranged on the surface of the fixing band, the fixing component is used for detachably connecting two sides of the fixing band to form a closed ring, and the fixing device further comprises a reinforcing band, one end of the reinforcing belt is connected with the front face of the fixing belt, the other end of the reinforcing belt is detachably connected with the front face of the fixing belt, and the fixing belt and the reinforcing belt are made of soft materials. The fixing band is fixed to the proper position of the arm of a patient through the fixing assembly, then the central venous catheter can be inserted into the corresponding position of the arm and located in the groove, the central venous catheter is preliminarily fixed through the C-shaped pipeline clamp in advance, and then the central venous catheter is secondarily fixed through connection of the reinforcing band and the fixing band. In the process, fixation is stable, and meanwhile adverse effects on a patient cannot be caused.

The invention discloses a newborn intensive care unit service platform, and relates to the technical field of medical informationization, and the newborn intensive care unit service platform is characterized in that semantic analysis is carried out on newborn consultation questions proposed by family members, and whether corresponding replies can be automatically generated or not is judged based on a preset medical knowledge base; if the corresponding reply cannot be automatically generated, the question is transferred to a manual reply end, and the medical staff manually answers the question; obtaining the state information of the medical personnel at the manual reply end, and calculating a reply priority value; and sending the consultation question to the medical staff corresponding to the maximum reply priority value to reply the consultation question. Therefore, when the system cannot answer the problem of the family member and needs to switch to the corresponding medical personnel for manual reply, the proper medical personnel can be reasonably selected for reply according to the actual condition, so that the timely information transmission and the accurate reply content are ensured, the anxiety emotion of the family member is reduced, and the trust relationship between the doctor and the patient is increased; and the adverse effect on the treatment of the newborns is reduced.

The invention discloses application of a compound DBP-64 in preparation of a medicine for preventing and treating magnaporthe oryzae, belongs to the field of prevention and treatment of plant fungal diseases, and finds that the compound DBP-64 has a remarkable effect on inhibiting the magnaporthe oryzae or / and other pathogenic fungi, can effectively inhibit the pathogenicity of magnaporthe oryzae spores in a concentration range of 3-50 ppm, and can be used for preparing a medicine for preventing and treating the magnaporthe oryzae. Especially, 50 ppm of the compound DBP-64 can completely prevent and treat rice blast, and the application method is simple. The compound DBP-64 and a magnaporthe oryzae spore liquid are mixed and sprayed for 0 hour, so that a certain prevention and treatment effect is achieved, and the compound DBP-64 can be used as a protection medicament in the early stage of magnaporthe oryzae infection and has a better effect; moreover, the rice sprayed with the compound is good in growth situation and free of obvious adverse effects, which indicates that the compound is safe to the rice and has practical significance in preventing rice blast.

Described are synthetic compounds having anti-inflammatory properties and optionally analgesic properties. These compounds are derivatives of FDA-approved anti-inflammatory, such as ibuprofen and indomethacin, and can be formed using reactions under microwave irradiation. Generally, the compounds contains a moiety of the parent drug, a triazolyl heterocycle, and a substituted or unsubstituted aryl group. In some forms, the compounds show anti-inflammatory properties and optionally analgesic properties with similar or higher efficiencies compared with their respective parent drugs, with additional advantages including no or reduced adverse effects (e.g., without ulcerogenic liability in the gastric) and / or selective inhibition of COX-2 over COX-1. Pharmaceutical compositions suitable for the delivery of the compounds to a subject in need thereof are disclosed. The pharmaceutical formulation can be administered by oral administration, parenteral administration, inhalation, mucosal administration, or a combination thereof. Methods for preventing or treating an inflammatory disease or disorder in a subject are also disclosed.

Methods for using bioadhesive and stearic interactions specific to copolymers with at least two moieties, to minimize adverse effects mediated by external influences on cell, tissue, organ system, and organism biology. Multifunctional copolymers have bioadhesive properties driven by electrostatic and hydrophobic interactions and passivation though hydrophilic moieties. These copolymers are useful for reducing rates of viral infectivity in target cells, and in reducing host morbidity and can be coforulated. These copolymers are useful for reducing ADC related, oncology therapy related, preservative related, systemic- pharmaceutical-therapy related, and / or topical ophthalmic active-pharmaceutical- ingredient related toxicity which can be manifest as a corneal epithelial toxicity. Methods for enhancing efficacy through coformulations with mucopenetration enhancing technologies and in coformulations with other actives that inhibit macropinocytosis allow for increasing efficacy in patient treatment approaches described herein. Coformulations with other actives ingredient will have therapeutic utility and prove beneficial in various settings. Formulations of these multifunctional copolymers for topical ophthalmic use are safe and well tolerated. Epithelial cells and the ocular surface including limbal stem cell and precursor corneal epithelial cells are treated with these copolymers to confer utility and patient benefit. Corneal nerves are similarly protected and corneal nerve cell damage is mitigated. Contact lenses provide an alternative method for delivering protective copolymers to the eye in these settings.

The present application relates to the field of pharmaceutical preparations, in particular to 5-amino-ketoglutaric acid metal complex, liposome and preparation method thereof. The 5-amino-ketoglutaric acid metal complex of the present application is formed by 5-amino-ketoglutaric acid and metal ion through coordination bond, and is a photosensitizer which can be used for photodynamic therapy of tumor. After ALA forms complex with metal ion, the reaction activity of amino and ketone groups in ALA molecule is reduced, the adverse influence of external environment on the molecule is delayed, and the stability is enhanced. Moreover, the co-aggregation of ALA and copper ion (or iron ion) to target tissue, the two means of ALA photodynamic therapy of tumor and copper (iron) ion promoting tumor cell apoptosis play drug efficacy, and have synergistic anti-tumor effect. The present application further provides liposome loaded with 5-amino-ketoglutaric acid metal complex, and preparation containing 5-amino-ketoglutaric acid metal complex or liposome.